Sympathetic Nervous System Modulation in Hypertension
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00491387|
Recruitment Status : Terminated (Adverse events reported with beta-blockers as primary therapy.)
First Posted : June 26, 2007
Results First Posted : April 19, 2011
Last Update Posted : February 7, 2018
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Drug: Metoprolol Succinate||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Sympathetic Nervous System Modulation in Hypertension by Beta-adrenergic Blockade|
|Study Start Date :||August 2007|
|Actual Primary Completion Date :||January 2009|
|Actual Study Completion Date :||January 2009|
Experimental: metoprolol succinate
Subjects will undergo I-123 MIBG testing before and after sustained-release beta-adrenergic blockade.
Drug: Metoprolol Succinate
Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
- Improvement in Sympathetic Cardiac Innervation as Measured by I-123 MIBG Heart - Mediastinum Ratio [ Time Frame: january 2018 ]24 subjects had baseline I-123 MIBG imaging. No subject completed all aspects of the protocol. The study was closed due to unfavorable publication related to metoprolol treatment for hypertension.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00491387
|Principal Investigator:||Myron C Gerson, M.D.||University of Cincinnati|